Gilde raises additional capital for healthcare service investments - Gilde Healthcare

Gilde raises additional capital for healthcare service investments

12 oktober 2011

Utrecht – Gilde Healthcare Partners has raised more than €50 million for its Gilde Healthcare Services fund. The fund invests growth capital in specialist clinics, elderly care, primary care, disease prevention, mental health, service laboratories and other healthcare service sectors.

“Innovative, expanding healthcare companies are in need of capital investment to support growth and this type of finance is often difficult to source from banks and governments in the current economic climate”

says Managing Partner Pieter van der Meer.

“As a value added partner providing growth capital Gilde can support the growth of various healthcare services companies.”, according to Jasper van Gorp, partner of the fund, “We are particularly focused on companies that provide quality care in a cost effective way.”

In 2010, the Gilde Healthcare Services fund invested in Stepping Stones Home & Care, a chain of small scale nursing homes for the elderly. The fund expects to announce an additional new investment in the coming weeks.

The fund complements existing Gilde Healthcare funds, which invest in companies developing medicines, diagnostic products and medical devices.

Meer nieuws

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17 oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15 oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14 oktober 2025